S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Indonesia says it has seized Iranian and Panamanian tankers
The Latest: France faces 3rd lockdown if curfew not enough
Trapped for 2 weeks, 11 workers rescued from China gold mine
One of 22 workers trapped in China gold mine rescued
Normal diets for trapped China miners as rescue continues
Average US price of gas up 10 cents a gallon to $2.45
The Latest: EU: Drug firms must fulfill vaccine contracts
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Indonesia says it has seized Iranian and Panamanian tankers
The Latest: France faces 3rd lockdown if curfew not enough
Trapped for 2 weeks, 11 workers rescued from China gold mine
One of 22 workers trapped in China gold mine rescued
Normal diets for trapped China miners as rescue continues
Average US price of gas up 10 cents a gallon to $2.45
The Latest: EU: Drug firms must fulfill vaccine contracts
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Indonesia says it has seized Iranian and Panamanian tankers
The Latest: France faces 3rd lockdown if curfew not enough
Trapped for 2 weeks, 11 workers rescued from China gold mine
One of 22 workers trapped in China gold mine rescued
Normal diets for trapped China miners as rescue continues
Average US price of gas up 10 cents a gallon to $2.45
The Latest: EU: Drug firms must fulfill vaccine contracts
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Indonesia says it has seized Iranian and Panamanian tankers
The Latest: France faces 3rd lockdown if curfew not enough
Trapped for 2 weeks, 11 workers rescued from China gold mine
One of 22 workers trapped in China gold mine rescued
Normal diets for trapped China miners as rescue continues
Average US price of gas up 10 cents a gallon to $2.45
The Latest: EU: Drug firms must fulfill vaccine contracts
Log in
ASX:VBS

Vectus Biosystems Limited (VBS.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that improves speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was founded in 2005 and is based in Rosebery, Australia.

MarketRank™

Overall MarketRank™

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:VBS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.vectusbiosystems.com.au
Phone61 2 9662 4144
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio2.02
Quick Ratio1.93

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$51,186.00
Price / Sales0.00
Cash FlowN/A
Price / Cash FlowN/A
Book ValueA($0.24) per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive VBS News and Ratings via Email

Sign-up to receive the latest news and ratings for VBS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vectus Biosystems Limited (VBS.AX) (ASX:VBS) Frequently Asked Questions

What stocks does MarketBeat like better than Vectus Biosystems Limited (VBS.AX)?

Wall Street analysts have given Vectus Biosystems Limited (VBS.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vectus Biosystems Limited (VBS.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Vectus Biosystems Limited (VBS.AX)'s key competitors?

Some companies that are related to Vectus Biosystems Limited (VBS.AX) include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical Limited (ACW.AX) (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB) and Algernon Pharmaceuticals (AGNPF).
View all of VBS's competitors.

Who are Vectus Biosystems Limited (VBS.AX)'s key executives?

Vectus Biosystems Limited (VBS.AX)'s management team includes the following people:
  • Dr. Karen Annette Duggan, CEO & Exec. Director
  • Mr. Robert John Waring BEc, CA, FCIS, FFin, FAICD, Company Sec.
  • Prof. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC, Consultant

What is Vectus Biosystems Limited (VBS.AX)'s stock symbol?

Vectus Biosystems Limited (VBS.AX) trades on the ASX under the ticker symbol "VBS."

How big of a company is Vectus Biosystems Limited (VBS.AX)?

Vectus Biosystems Limited (VBS.AX) has a market capitalization of $0.00 and generates $51,186.00 in revenue each year.

What is Vectus Biosystems Limited (VBS.AX)'s official website?

The official website for Vectus Biosystems Limited (VBS.AX) is www.vectusbiosystems.com.au.

How can I contact Vectus Biosystems Limited (VBS.AX)?

The company can be reached via phone at 61 2 9662 4144.

This page was last updated on 1/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.